Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)

Sponsor
Fisher and Paykel Healthcare (Industry)
Overall Status
Completed
CT.gov ID
NCT00750165
Collaborator
(none)
32
1
1
8
4

Study Details

Study Description

Brief Summary

Nasal Continuous Positive Airway Pressure (CPAP) is the standard therapy for obstructive sleep apnea hypopnea syndrome (OSAHS). This is most commonly administered as a single positive pressure that has been individualized for the patient to prevent obstructive respiratory events. However, the therapeutic pressure may vary by sleep stage and body position within a single night and may change over the course of several nights. One approach to dealing with this variability is the use of automatically adjusting CPAP that responds to patient breathing patterns with alterations in the delivered pressure. This study is designed to determine the effectiveness of using the energy spectrum analysis of flow signals to automatically adjust CPAP pressure and improve sleep variables. Thirty subjects who require CPAP will be recruited from the NYU sleep disorders center. Following diagnostic studies (either split night or full night) the subject will undergo a night of treatment with the Fisher and Paykel Healthcare AutoPAP. Efficacy of treatment will be evaluated based on normalization of sleep disordered breathing while treated with the AutoPAP.

Condition or Disease Intervention/Treatment Phase
  • Device: SleepStyle 200 Auto Series CPAP Humidifier
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Auto CPAP Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome.
Study Start Date :
May 1, 2007
Actual Primary Completion Date :
Jan 1, 2008
Actual Study Completion Date :
Jan 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Experimental: Titration Night

Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device

Device: SleepStyle 200 Auto Series CPAP Humidifier
The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
Other Names:
  • HC254
  • Outcome Measures

    Primary Outcome Measures

    1. Apnea Hypopnea Index (AHI) [1 night]

      The Apnea Hypopnea Index (AHI) measure of severity of Obstructive Sleep Apnea (OSA). It is a calculation of the number of apnea events and the number of hypopnea events divided by the total sleep time. Mild OSA is characterized between 5-15 events per hour. Moderate OSA is characterized as 15-30 events per hour. Severe OSA is characterized as greater than 30 events per hour.

    Secondary Outcome Measures

    1. Percent of Time With Less Than 90% Oxygen Saturation [1 Night]

      Oxygen saturation is a measurement of the amount of oxygen present in the blood. An oxygen saturation of less than 90% is considered low, resulting in hypoxemia. Normal blood oxygen level is considered between 95-100%.

    2. Respiratory Disturbance Index (RDI) [1 Night]

      Similar to AHI, the RDI is a calculation of the total number of respiratory disturbances in sleep. The calculation includes apneas and hypopneas, but also includes respiratory effort related arousals.

    3. Arousal Index (AI) [1 Night]

      The Arousal Index is a calculation of the frequency of awakenings per hour of sleep. The higher the number, the more awakenings per hour.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • AHI >15 on the diagnostic portion of the study

    • 18 years of age

    Exclusion Criteria:
    • Significant Central Apnea

    • Congestive Heart Failure

    • Inability to give informed consent

    • Patient intolerance to CPAP

    • Anatomical or physiological conditions making CPAP therapy inappropriate

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NYU Sleep Disorders Center New York New York United States 10016

    Sponsors and Collaborators

    • Fisher and Paykel Healthcare

    Investigators

    • Principal Investigator: David M Rapoport, MD, NYU School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Fisher and Paykel Healthcare
    ClinicalTrials.gov Identifier:
    NCT00750165
    Other Study ID Numbers:
    • OSA CPAP; 254 Validation, NYU
    First Posted:
    Sep 10, 2008
    Last Update Posted:
    Apr 9, 2019
    Last Verified:
    Mar 1, 2019
    Keywords provided by Fisher and Paykel Healthcare
    Additional relevant MeSH terms:

    Study Results

    Participant Flow

    Recruitment Details
    Pre-assignment Detail
    Arm/Group Title Titration Night
    Arm/Group Description Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device SleepStyle 200 Auto Series CPAP Humidifier: The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
    Period Title: Overall Study
    STARTED 32
    COMPLETED 21
    NOT COMPLETED 11

    Baseline Characteristics

    Arm/Group Title Titration Night
    Arm/Group Description Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device SleepStyle 200 Auto Series CPAP Humidifier: The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
    Overall Participants 21
    Age (years) [Mean (Full Range) ]
    Mean (Full Range) [years]
    51
    Sex: Female, Male (Count of Participants)
    Female
    0
    0%
    Male
    21
    100%
    Race and Ethnicity Not Collected (Count of Participants)
    Region of Enrollment (participants) [Number]
    United States
    21
    100%

    Outcome Measures

    1. Primary Outcome
    Title Apnea Hypopnea Index (AHI)
    Description The Apnea Hypopnea Index (AHI) measure of severity of Obstructive Sleep Apnea (OSA). It is a calculation of the number of apnea events and the number of hypopnea events divided by the total sleep time. Mild OSA is characterized between 5-15 events per hour. Moderate OSA is characterized as 15-30 events per hour. Severe OSA is characterized as greater than 30 events per hour.
    Time Frame 1 night

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Titration Night
    Arm/Group Description Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device SleepStyle 200 Auto Series CPAP Humidifier: The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
    Measure Participants 21
    Mean (Full Range) [events per hour]
    2.4
    2. Secondary Outcome
    Title Percent of Time With Less Than 90% Oxygen Saturation
    Description Oxygen saturation is a measurement of the amount of oxygen present in the blood. An oxygen saturation of less than 90% is considered low, resulting in hypoxemia. Normal blood oxygen level is considered between 95-100%.
    Time Frame 1 Night

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Titration Night
    Arm/Group Description Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device SleepStyle 200 Auto Series CPAP Humidifier: The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
    Measure Participants 21
    Mean (Full Range) [percentage of total sleep time]
    1.4
    3. Secondary Outcome
    Title Respiratory Disturbance Index (RDI)
    Description Similar to AHI, the RDI is a calculation of the total number of respiratory disturbances in sleep. The calculation includes apneas and hypopneas, but also includes respiratory effort related arousals.
    Time Frame 1 Night

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Titration Night
    Arm/Group Description Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device SleepStyle 200 Auto Series CPAP Humidifier: The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
    Measure Participants 21
    Mean (Full Range) [events per hour]
    7.1
    4. Secondary Outcome
    Title Arousal Index (AI)
    Description The Arousal Index is a calculation of the frequency of awakenings per hour of sleep. The higher the number, the more awakenings per hour.
    Time Frame 1 Night

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Titration Night
    Arm/Group Description Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device SleepStyle 200 Auto Series CPAP Humidifier: The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
    Measure Participants 21
    Mean (Full Range) [events per hour]
    16.2

    Adverse Events

    Time Frame 1 night
    Adverse Event Reporting Description
    Arm/Group Title Titration Night
    Arm/Group Description Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device SleepStyle 200 Auto Series CPAP Humidifier: The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
    All Cause Mortality
    Titration Night
    Affected / at Risk (%) # Events
    Total 0/21 (0%)
    Serious Adverse Events
    Titration Night
    Affected / at Risk (%) # Events
    Total 0/21 (0%)
    Other (Not Including Serious) Adverse Events
    Titration Night
    Affected / at Risk (%) # Events
    Total 6/21 (28.6%)
    Investigations
    Disruption of Sleep Due to Lab Environment 4/21 (19%) 4
    Respiratory, thoracic and mediastinal disorders
    Mask Discomfort 1/21 (4.8%) 1
    Difficulty Exhaling Due to Pressure 1/21 (4.8%) 1

    Limitations/Caveats

    [Not Specified]

    More Information

    Certain Agreements

    Principal Investigators are NOT employed by the organization sponsoring the study.

    There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/Title Clinical Research Scientist
    Organization Fisher and Paykel Healthcare
    Phone +64 9 574 0123 ext 7044
    Email cpaptrial@fphcare.co.nz
    Responsible Party:
    Fisher and Paykel Healthcare
    ClinicalTrials.gov Identifier:
    NCT00750165
    Other Study ID Numbers:
    • OSA CPAP; 254 Validation, NYU
    First Posted:
    Sep 10, 2008
    Last Update Posted:
    Apr 9, 2019
    Last Verified:
    Mar 1, 2019